February 13, 2002
AMERIPATH TO REPORT FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR
ENDED DECEMBER 31, 2001
- Tuesday, February 19, 2002, Before Market -
Riviera Beach, FL, February 13, 2002 – AmeriPath, Inc. (Nasdaq:PATH),
one of the nation’s leading providers of anatomic pathology
services, today announced that it plans to release its complete
financial results for the fourth quarter and year ended December
31, 2001 on Tuesday, February 19, 2002, before the market opens.
The Company will broadcast its full financial results conference
call on Tuesday, February 19, 2002, at 10:00 a.m. Eastern Time
over the Internet. The call will by hosted by James C. New, Chairman
and Chief Executive Officer, and Gregory A. Marsh, Vice President
and Chief Financial Officer. All stockholders and investors are
encouraged to participate. This event is available by visiting
the Company’s website located at http://www.ameripath.com,
or through CCBN’s Street Events website, located at http://www.streetevents.com.
Listeners should go to one of these websites at least fifteen minutes
before the call to register and to download and install any necessary
audio software. For those unable to attend the live webcast, a
replay will be available on these websites for the next 60 days.
There is no charge to access the event. A replay of the call will
also be available by telephone beginning at 12:00 p.m., February
19th to 12:00 p.m., February 21st. The dial-in number for the telephone
replay is 800-633-8284, ID #20353163.
AmeriPath is a leading national provider of cancer diagnostics,
genomics, and related information services. During the first nine
months of 2001, AmeriPath diagnosed approximately 2.9 million tissue
biopsies, and interpreted approximately 1.6 million Pap smears.
The company’s extensive diagnostics infrastructure includes
over 400 pathologists and doctorate-level scientists providing
services to 42 independent pathology laboratories, more than 200
hospitals, the Center for Advanced Diagnostics (CAD) and Dermpath
Diagnostics, a division of AmeriPath. CAD provides specialized
diagnostic testing and information services including Fluorescence
In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis, Polymerase
Chain Reaction (PCR), Molecular Genetics, Cytogenetics and HPV
Typing. AmeriPath has over 60 board-certified dermatopathologists
supporting Dermpath Diagnostics, one of the country’s leading
providers of dermatopathology services in the growing skin diagnostic
market. Additionally, AmeriPath provides clinical trial and research
development support to firms involved in developing new cancer
and genomic diagnostics and therapeutics.
